White Andrew C, Kumpe David A, Roark Christopher D, Case David E, Seinfeld Joshua
Department of Neurosurgery, University of Colorado Hospital, Aurora, Colorado, USA; Department of Radiology, University of Louisville, Louisville, Kentucky, USA.
Department of Neurosurgery, University of Colorado Hospital, Aurora, Colorado, USA; Department of Radiology, University of Colorado Hospital, Aurora, Colorado, USA.
World Neurosurg. 2018 Jul;115:e97-e104. doi: 10.1016/j.wneu.2018.03.190. Epub 2018 Apr 5.
To evaluate patterns, predictors, and outcomes of postprocedure delayed hemorrhage (PPDH) following flow diversion therapy for intracranial aneurysm treatment.
From 2012 to 2016, 50 patients with 52 aneurysms were treated with the Pipeline embolization device. Device placement was performed as a standalone therapy or with adjunctive coil embolization. Patients underwent dual antiplatelet therapy for 6 months after treatment. Medical comorbidities; aneurysm traits; and treatment factors, including platelet function testing, were studied. Statistical analysis was performed using cross-tabulation.
Six PPDHs (12%) occurred 2-16 days (mean 6.8 days) after Pipeline placement, manifesting as 1 of 2 distinct patterns: convexity subarachnoid hemorrhage (cSAH) (n = 4) or lobar intraparenchymal hemorrhage (IPH) (n = 2). All PPDHs occurred ipsilateral to the device; 1 IPH occurred ipsilateral but in a different arterial territory. PPDH occurred in both treated anterior communicating artery aneurysms. Cases of PPDH demonstrated on average lower P2Y12 reaction unit values at the time of treatment. Platelet function testing at the time of hemorrhage was consistently hypertherapeutic. Patients with cSAH had only minimal worsening of modified Rankin Scale score at the time of discharge, whereas the 2 patients with IPH experienced significant deterioration.
PPDH is a poorly understood complication following flow diversion therapy that can result in significant morbidity. In our experience, nonaneurysmal cSAH does not result in poor clinical outcomes, whereas IPH leads to long-term deficits or death. As previously suggested, there appears to be a correlation between low P2Y12 reaction unit values and PPDH.
评估颅内动脉瘤血流导向治疗术后迟发性出血(PPDH)的模式、预测因素及预后。
2012年至2016年,50例患者的52个动脉瘤接受了Pipeline栓塞装置治疗。装置置入作为单独治疗或联合弹簧圈栓塞进行。治疗后患者接受6个月的双重抗血小板治疗。研究了合并症、动脉瘤特征以及包括血小板功能检测在内的治疗因素。采用交叉表进行统计分析。
6例(12%)PPDH发生在Pipeline置入后2 - 16天(平均6.8天),表现为2种不同模式之一:脑凸面蛛网膜下腔出血(cSAH)(n = 4)或脑叶脑实质内出血(IPH)(n = 2)。所有PPDH均发生在装置同侧;1例IPH发生在同侧但位于不同动脉区域。PPDH发生在两个接受治疗的前交通动脉瘤中。PPDH病例在治疗时平均P2Y12反应单位值较低。出血时的血小板功能检测始终处于过度治疗状态。cSAH患者出院时改良Rankin量表评分仅略有恶化,而2例IPH患者病情显著恶化。
PPDH是血流导向治疗后一种了解不足但可导致严重发病的并发症。根据我们的经验,非动脉瘤性cSAH不会导致不良临床结局,而IPH会导致长期功能缺损或死亡。如先前所述,低P2Y12反应单位值与PPDH之间似乎存在相关性。